Current News
Bioheart Partners With Stemlogix to Offer Products to the Veterinary Market -- Bioheart, Inc. (BHRT.OB), a company focused on developing stem cell therapies for heart disease announced that they have entered into an agreement with Stemlogix, LLC, a veterinary regenerative medicine company, to provide additional cellular products and services to the veterinary market.
December 20, 2011
Bioheart Files With the FDA to Begin the ANGEL Trial -- Bioheart, Inc. (BHRT.OB) announced that they have completed an Investigational New Drug (IND) application to the FDA for the ANGEL trial. The clinical protocol is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell) in patients with chronic ischemic cardiomyopathy.
December 6, 2011
Bioheart Enters Into $3,000,000 Financing Agreement -- Bioheart, Inc. (BHRT.OB) a leader in the field of stem cell therapy for the treatment of damaged hearts, today announced that it entered into a $3M standby equity purchase agreement, previously announced in October.
November 15, 2011
William P. Murphy Jr., MD, Discusses Bioheart on American Investor Documentary -- Bioheart, Inc. (OTCBB:BHRT) today released a short clip from the American Investor Documentary. William P. Murphy Jr., MD talks about the unrealized opportunities with the Bioheart technology and the strong management team leading the efforts.
November 14, 2011
Bioheart Presents Summary of Clinical Data From Past 10 Years -- Bioheart, Inc. (OTCBB:BHRT) was among top scientists and physicians presenting cutting edge data at the Controversies and Advances in the Treatment of Cardiovascular Disease Conference in Los Angeles last week.
October 18, 2011
Bioheart Presenting at Advances in the Treatment of Cardiovascular Diseases Meeting -- Bioheart, Inc. (OTCBB:BHRT) announced today that it will present a summary of data on the use of adult muscle stem cells (immature myoblasts) to treat advanced heart failure at the Controversies and Advances in the Treatment of Cardiovascular Disease Conference at Beverly Hills Hotel in Los Angeles on October 12th - 14th.
October 12, 2011
Airspeed Equity and Bioheart Announce Launch of MyoStim and Biopace Products -- Bioheart, Inc. (OTCBB:BHRT) and Airspeed Equity LLC, a private investment, entrepreneurial capital management firm, today announced four major products - MyoStim Lab Culture Stimulator, Limb Blood Flow Stimulator, and Implantable Heart Pacemaker and the Biopace Biological Pacemaker.
October 11, 2011
Bioheart Announces $3,000,000 Equity Facility -- Bioheart, Inc. (OTCBB:BHRT) a leader in the field of muscle-derived stem cell therapy for the treatment of scar tissue in damaged hearts, today announced that it has agreed on terms with an investor to provide the Company with up to $3,000,000 in equity financing via sales of registered common stock over a 24 month term.
October 6, 2011
Bioheart's MARVEL Trial Published in the American Heart Journal -- Bioheart, Inc. (OTCBB:BHRT), announced today that their clinical paper has been published in a prominent peer reviewed medical journal.
October 4, 2011
Bioheart Presents Clinical Data at the Cell Therapy Commercialization Summit -- Bioheart, Inc. (OTCBB:BHRT) today announced it was one of the presenters at the Cell Therapy Commercialization Summit in Boston along with Genzyme, Genentech, Geron and others.
September 22, 2011
Bioheart Pre-Releases Short Video Clip of American Investor Documentary -- Bioheart, Inc. (OTCBB:BHRT) today released a short clip from the American Investor Documentary. The full program is scheduled to air later this month.
September 21, 2011
American Investor Reporter, Kimberley Cole Interviews Mike Tomas, President & CEO of Bioheart for Launch of New Investor Docu-Series -- Bioheart, Inc. (OTCBB:BHRT) today announced that The American Investor, producers of the national and international award winning program ABC's "Money Talks", ABC's "MoneyScope" and the American Consumer has initiated coverage of Bioheart as one of the first in a new series of financially related documentaries.
September 20, 2011
Bioheart Announces US FDA Clinical Program Using Adipose Cells -- Bioheart, Inc. (OTCBB:BHRT) announced that they will begin a US clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the FDA to begin a Phase I study in the US.
September 14, 2011